The potential for efficacy of the modified (ICP 34.5−) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study

Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial

James M. Markert, Michael D. Medlock, Samuel D. Rabkin et al. · Gene Therapy · 2000 · 978 citations

Medicine, Biomedical Sciences, Oncology +9

Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma

R Rampling, G. Cruickshank, Vakis Papanastassiou et al. · Gene Therapy · 2000 · 598 citations

Medicine, Molecular Biology, Oncology +10

Genetic Studies with Herpes Simplex Virus Type 1. The Isolation of Temperature-sensitive Mutants, their Arrangement into Complementation Groups and Recombination Analysis Leading to a Linkage Map

S. M. Brown, D.A. Ritchie, J. H. Subak‐Sharpe · Journal of General Virology · 1973 · 386 citations

Life Sciences, Genetics, Microbiology +11

Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the 'a' sequence

Alasdair Maclean, M. Ul-Fareed, L. Robertson et al. · Journal of General Virology · 1991 · 254 citations

Life Sciences, Genetics, Infectious Diseases +14

Therapy of experimental human brain tumors using a neuroattenuated herpes simplex virus mutant.

Santosh Kesari, B. Randazzo, T. Valyi-Nagy et al. · PubMed · 1995 · 123 citations

Medicine, Neuroscience, Oncology +11